Peptides for Energy: Mitochondrial Mechanisms and What They Are Worth

Fatigue is not one thing, which is why most peptide answers to it are wrong. Someone who is tired because their mitochondria are producing less ATP than they used to has a different problem from someone who is tired because they sleep badly, and a different problem again from someone who is tired because their thyroid is underactive. Only the first has anything to do with the compounds on this page.

That is the honest framing, and it disqualifies most of what gets marketed for energy. What follows is the compounds with a plausible mechanism, sorted by how much evidence sits behind them, and an explicit note on where each one falls short.

Rule Out the Boring Causes First

This is not a disclaimer, it is the highest yield step on the page. Iron deficiency, hypothyroidism, sleep apnoea, low vitamin D and poor sleep quality account for the overwhelming majority of persistent fatigue, and every one of them is cheap to test and treatable. A peptide protocol layered on top of undiagnosed anaemia will not work, and the money would have been better spent on a blood panel.

If those have been checked and the fatigue is still there, the mitochondrial argument becomes worth considering. If they have not been checked, nothing below is the right next step.

MOTS-c: The Mitochondrial Peptide

MOTS-c is unusual in that it is encoded in mitochondrial DNA rather than nuclear DNA, which makes it one of a small set of mitochondrial derived peptides. It appears to act through AMPK activation, the same energy sensing pathway that exercise and metformin engage, and the published work associates it with improved insulin sensitivity and enhanced metabolic flexibility.

The evidence base is mostly rodent and cell culture. What makes it more interesting than most compounds at that evidence level is the observational human data: higher endogenous MOTS-c levels have been associated with markers of healthier ageing, and levels decline with age. That is correlational and does not establish that supplementing helps, but it is a more coherent story than most of this category offers.

Typical protocols run 5 to 10mg weekly, often split into two or three subcutaneous doses, in blocks of four to six weeks. The MOTS-c page covers the mechanism in detail.

SS-31: The One With Actual Clinical Trials

SS-31, also called elamipretide, is the compound in this category with the strongest evidence, and that is because it has been through real clinical trials rather than because the community likes it.

Its mechanism is specific and physically interesting. It binds cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, and stabilises the cristae architecture that the electron transport chain depends on. Damaged cardiolipin means a leaky, inefficient membrane and less ATP per unit of substrate. Stabilising it addresses the structural problem rather than pushing harder on a broken system.

It has been trialled in primary mitochondrial myopathy and in Barth syndrome, with mixed results: some endpoints improved, others did not reach significance. That is more than any other compound here can claim, and it is also a reminder that a good mechanism does not guarantee a clinical effect. For fatigue in an otherwise healthy person, there is no trial at all.

Research grade material is sold as SS-31 and occasionally under the elamipretide name. Protocols in circulation run in the low milligrams per day for short blocks, extrapolated from the trial dosing rather than derived from any study in healthy subjects.

NAD+ and the Precursor Question

NAD+ is a coenzyme central to the electron transport chain, and its levels fall with age. That much is well established. What is contested is whether raising them helps, and whether injecting NAD+ directly is a sensible way to do it.

The molecule is large and charged, which makes cellular uptake of intact NAD+ questionable. It may well be broken down to nicotinamide and reassembled inside the cell, in which case injecting the finished coenzyme offers no advantage over an oral precursor like NMN or NR at a fraction of the cost and inconvenience. Subcutaneous NAD+ also stings considerably, which is a practical objection people discover rather than read about.

The honest position is that NAD+ status matters and the delivery route is unsettled. Anyone starting here would get more certainty per dollar from an oral precursor.

Epithalon: A Different Mechanism Entirely

Epithalon is a four amino acid peptide from the Russian bioregulator research programme, proposed to act on telomerase and on pineal regulation of melatonin. The energy connection is indirect: better sleep architecture produces better daytime energy, and the melatonin pathway is where the claim sits.

The evidence is genuinely difficult to assess. Most of it comes from a small number of Russian research groups, much of it is decades old, and independent replication is thin. It is a compound with an interesting hypothesis and an evidence base that has not been stress tested by anyone outside the original programme. Protocols run 5 to 10mg daily in short courses of ten to twenty days, a few times a year. The epithalon page covers what the original work actually reported.

The Nootropics, Which Are Not Energy Compounds

Semax and selank get recommended for fatigue constantly and they are doing something different. Both are Russian developed peptides acting on neurotransmitter systems, semax through BDNF and dopaminergic modulation, selank through GABAergic and anxiolytic pathways. Neither touches mitochondrial function.

What they can do is change the subjective experience of being tired. Fatigue that is really attentional, where the problem is difficulty initiating and sustaining focus rather than a lack of physical capacity, sometimes responds to that kind of intervention. It is worth being clear that this is symptomatic rather than mechanistic: the underlying energy production is unchanged, and if the cause is mitochondrial or nutritional then masking it is not the same as fixing it.

They are also the compounds in this list most likely to produce a same day noticeable effect, which is why they get recommended, and noticeable is not the same as useful. The semax page and the selank page cover both properly. Pantheon lists semax and selank as direct products.

Ranking What Is Actually Here

How To Actually Approach This

• Test first. Full blood count, ferritin, thyroid panel and vitamin D. If any of those is off, that is the answer and no peptide will substitute for correcting it.
• Change one thing at a time. Starting three compounds together means no observed effect can be attributed to any of them, and fatigue is a subjective endpoint that is unusually prone to expectation effects.
• Set a measurable endpoint before starting. Resting heart rate, training output, hours of usable focus, anything with a number. Impressions after four weeks are not data.
• Give it four to six weeks. Mitochondrial adaptation is slow. A judgement at week one is measuring expectation.
• Expect a modest effect at best. Nothing here matches what fixing sleep or correcting iron deficiency does for someone who needs it.

If the goal is a structured protocol rather than a single compound, the stack builder lays out selection and timing, the longevity page covers the overlapping compound set, and the cycle guide covers how long each block should run.

Key Takeaways

• Fatigue has common, testable causes that no peptide substitutes for correcting
• SS-31 has the strongest evidence, from trials in mitochondrial disease rather than in healthy people
• MOTS-c has the most coherent mechanism at its evidence level, acting through AMPK
• Injectable NAD+ has an unsettled delivery route and oral precursors cost far less
• Epithalon rests largely on one research programme with thin independent replication
• Semax and selank change how fatigue feels without touching how energy is produced
• Change one variable at a time and set a measurable endpoint, because fatigue is highly susceptible to expectation

Frequently Asked Questions

What is the best peptide for energy?

SS-31 has the strongest evidence, because it has been through actual clinical trials in mitochondrial disease, though none of that work was done in otherwise healthy people. MOTS-c has the most coherent mechanism at its evidence level, acting on the AMPK pathway with human observational data behind it. Neither compares to correcting an iron deficiency or a thyroid problem if one of those is the actual cause.

Does MOTS-c actually increase energy?

The mechanism is plausible and the human evidence is observational rather than interventional. MOTS-c is encoded in mitochondrial DNA, acts through AMPK activation, and higher endogenous levels correlate with markers of healthier ageing while levels fall with age. What has not been demonstrated is that supplementing raises the relevant outcomes in people. Most of the direct evidence is rodent and cell culture.

Is injectable NAD+ better than oral NMN?

Not clearly, and it is considerably more expensive and less comfortable. NAD+ is a large charged molecule whose intact cellular uptake is questionable, and it may simply be broken down and reassembled inside the cell, in which case an oral precursor achieves the same thing more cheaply. Subcutaneous NAD+ also stings substantially. The deficit with age is real; the case for the injectable route specifically is not settled.

Do semax and selank help with fatigue?

They change how fatigue feels rather than how energy is produced. Both act on neurotransmitter systems, semax through BDNF and dopaminergic pathways and selank through GABAergic ones, and neither touches mitochondrial function. For fatigue that is really an attention problem, that can be useful. For fatigue caused by anaemia or poor sleep, it masks the signal without addressing the cause.

How long before a peptide for energy shows an effect?

Four to six weeks for anything working through mitochondrial adaptation, which is slow by nature. Semax and selank are the exception and can produce a same day subjective change, which is precisely why they get over-recommended. Judging a mitochondrial compound at week one is measuring expectation rather than effect, and fatigue is an unusually suggestible endpoint.

What should I check before trying any of this?

A full blood count, ferritin, a thyroid panel and vitamin D, at minimum. Iron deficiency, hypothyroidism, sleep apnoea and poor sleep quality account for most persistent fatigue and all are cheap to identify and treatable. A peptide protocol layered on top of an undiagnosed deficiency will not work, and the money would have bought a far better answer as a blood panel.